The number of Crohn's disease patients needing a permanent stoma has declined significantly with the rise of biologic drugs that treat anorectal disease, according to researchers at the University of Bologna. They said biological treatments have "modified the management of large bowel Crohn's disease with anorectal involvement, leading to fewer permanent ileostomies and more patients with anal function."

Related Summaries